-
GeneQuantum Healthcare’s GQ1005 ADC Receives CDE Clearance for Phase III Breast Cancer Trial
•
SUZHOU—GeneQuantum Healthcare (Suzhou) Co., Ltd has received clearance from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to proceed with a Phase III clinical study for its antibody drug conjugate (ADC), GQ1005, targeting HER2 in patients with non-surgical/metastatic breast cancer. Preclinical studies have shown that…
-
GeneQuantum Appoints Dr. Lingyu Zhu as Chief Business Strategy and Development Officer
•
SUZHOU—GeneQuantum, a leading player in the biotech industry known for its cutting-edge enzymatic site-specific conjugation technologies, has announced the appointment of Dr. Lingyu Zhu as its Chief Business Strategy and Development Officer. Dr. Zhu’s name surfaced in the recent 8th Asia-Pacific Biopharma Partnership Summit’s list of pharmaceutical business development leaders,…
-
Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has entered into a partnership with China-based GeneQuantum Healthcare. The collaboration aims to integrate the core technology platforms and professional expertise of both companies to empower the early discovery…
